THE Therapeutic Goods Administration is seeking comments on proposed additional Required Advisory Statements for Medicine Labels (RASML) for sedating antihistamines.
The proposal aims to ensure health professionals, parents and carers are adequately cautioned against the use of first-generation sedating antihistamines in children, particularly those aged under two.
The TGA is also proposing editorial changes in order to harmonise the entries for each of these medicines as far as possible.
Interested parties should respond by Thu 21 Jun 2018 - tga.gov.au.
A separate consultation is also in place for RASML relating to miconazole and fluconazole medications, with a proposed warning about warfarin - tga.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 May 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 May 18
